A novel HRAS mutation independently contributes to left ventricular hypertrophy in a family with a known MYH7 mutation

Maria Elena Sana, Lawrence Quilliam, Andrea Spitaleri, Laura Pezzoli, Daniela Marchetti, Chiara Lodrini, Elisabetta Candiago, Anna Rita Lincesso, Paolo Ferrazzi, Maria Iascone

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Several genetic conditions can lead to left ventricular hypertrophy (LVH). Among them, hypertrophic cardiomyopathy (HCM), caused by mutations in sarcomere genes, is the most common inherited cardiac disease. Instead, RASopathies, a rare class of disorders characterized by neuro-cardio-facial-cutaneous abnormalities and sometimes presenting with LVH, are caused by mutations in the RAS-MAPK pathway. We report on a 62-years-old male who presented isolated severe obstructive LVH but did not carry the sarcomere mutation previously identified in his affected relatives. By exome sequencing, we detected a novel mutation in HRAS gene (NM-005343.2:p.Arg68Trp), present also in the proband's daughter, who showed mild LVH and severe intellectual disability. The cardiac phenotype was indistinguishable between family members carrying either mutation. In silico studies suggested that the mutated HRAS protein is constitutionally activated. Consistently, functional characterization in vitro confirmed elevated HRAS-GTP accumulation and downstream RAS-MAPK pathway activation that are known to drive cell proliferation in LVH. Our study emphasizes the role of RAS signaling in cardiac hypertrophy and highlights the complexity in differential diagnosis of RASopathies. In fact, the mild features of RASopathy and the recurrence of sarcomeric HCM in this family delayed the correct diagnosis until comprehensive genetic testing was performed.

Original languageEnglish (US)
Article numbere0168501
JournalPLoS One
Volume11
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Left Ventricular Hypertrophy
hypertrophy
Genes
mutation
Mutation
Cell proliferation
Guanosine Triphosphate
Sarcomeres
Hypertrophic Cardiomyopathy
sarcomeres
Chemical activation
cardiomyopathy
Skin Abnormalities
Exome
Testing
Delayed Diagnosis
Cardiomegaly
Genetic Testing
Proteins
Nuclear Family

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

A novel HRAS mutation independently contributes to left ventricular hypertrophy in a family with a known MYH7 mutation. / Sana, Maria Elena; Quilliam, Lawrence; Spitaleri, Andrea; Pezzoli, Laura; Marchetti, Daniela; Lodrini, Chiara; Candiago, Elisabetta; Lincesso, Anna Rita; Ferrazzi, Paolo; Iascone, Maria.

In: PLoS One, Vol. 11, No. 12, e0168501, 01.12.2016.

Research output: Contribution to journalArticle

Sana, ME, Quilliam, L, Spitaleri, A, Pezzoli, L, Marchetti, D, Lodrini, C, Candiago, E, Lincesso, AR, Ferrazzi, P & Iascone, M 2016, 'A novel HRAS mutation independently contributes to left ventricular hypertrophy in a family with a known MYH7 mutation', PLoS One, vol. 11, no. 12, e0168501. https://doi.org/10.1371/journal.pone.0168501
Sana, Maria Elena ; Quilliam, Lawrence ; Spitaleri, Andrea ; Pezzoli, Laura ; Marchetti, Daniela ; Lodrini, Chiara ; Candiago, Elisabetta ; Lincesso, Anna Rita ; Ferrazzi, Paolo ; Iascone, Maria. / A novel HRAS mutation independently contributes to left ventricular hypertrophy in a family with a known MYH7 mutation. In: PLoS One. 2016 ; Vol. 11, No. 12.
@article{e2cb6819de154f57a4365494d0b28ea3,
title = "A novel HRAS mutation independently contributes to left ventricular hypertrophy in a family with a known MYH7 mutation",
abstract = "Several genetic conditions can lead to left ventricular hypertrophy (LVH). Among them, hypertrophic cardiomyopathy (HCM), caused by mutations in sarcomere genes, is the most common inherited cardiac disease. Instead, RASopathies, a rare class of disorders characterized by neuro-cardio-facial-cutaneous abnormalities and sometimes presenting with LVH, are caused by mutations in the RAS-MAPK pathway. We report on a 62-years-old male who presented isolated severe obstructive LVH but did not carry the sarcomere mutation previously identified in his affected relatives. By exome sequencing, we detected a novel mutation in HRAS gene (NM-005343.2:p.Arg68Trp), present also in the proband's daughter, who showed mild LVH and severe intellectual disability. The cardiac phenotype was indistinguishable between family members carrying either mutation. In silico studies suggested that the mutated HRAS protein is constitutionally activated. Consistently, functional characterization in vitro confirmed elevated HRAS-GTP accumulation and downstream RAS-MAPK pathway activation that are known to drive cell proliferation in LVH. Our study emphasizes the role of RAS signaling in cardiac hypertrophy and highlights the complexity in differential diagnosis of RASopathies. In fact, the mild features of RASopathy and the recurrence of sarcomeric HCM in this family delayed the correct diagnosis until comprehensive genetic testing was performed.",
author = "Sana, {Maria Elena} and Lawrence Quilliam and Andrea Spitaleri and Laura Pezzoli and Daniela Marchetti and Chiara Lodrini and Elisabetta Candiago and Lincesso, {Anna Rita} and Paolo Ferrazzi and Maria Iascone",
year = "2016",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0168501",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - A novel HRAS mutation independently contributes to left ventricular hypertrophy in a family with a known MYH7 mutation

AU - Sana, Maria Elena

AU - Quilliam, Lawrence

AU - Spitaleri, Andrea

AU - Pezzoli, Laura

AU - Marchetti, Daniela

AU - Lodrini, Chiara

AU - Candiago, Elisabetta

AU - Lincesso, Anna Rita

AU - Ferrazzi, Paolo

AU - Iascone, Maria

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Several genetic conditions can lead to left ventricular hypertrophy (LVH). Among them, hypertrophic cardiomyopathy (HCM), caused by mutations in sarcomere genes, is the most common inherited cardiac disease. Instead, RASopathies, a rare class of disorders characterized by neuro-cardio-facial-cutaneous abnormalities and sometimes presenting with LVH, are caused by mutations in the RAS-MAPK pathway. We report on a 62-years-old male who presented isolated severe obstructive LVH but did not carry the sarcomere mutation previously identified in his affected relatives. By exome sequencing, we detected a novel mutation in HRAS gene (NM-005343.2:p.Arg68Trp), present also in the proband's daughter, who showed mild LVH and severe intellectual disability. The cardiac phenotype was indistinguishable between family members carrying either mutation. In silico studies suggested that the mutated HRAS protein is constitutionally activated. Consistently, functional characterization in vitro confirmed elevated HRAS-GTP accumulation and downstream RAS-MAPK pathway activation that are known to drive cell proliferation in LVH. Our study emphasizes the role of RAS signaling in cardiac hypertrophy and highlights the complexity in differential diagnosis of RASopathies. In fact, the mild features of RASopathy and the recurrence of sarcomeric HCM in this family delayed the correct diagnosis until comprehensive genetic testing was performed.

AB - Several genetic conditions can lead to left ventricular hypertrophy (LVH). Among them, hypertrophic cardiomyopathy (HCM), caused by mutations in sarcomere genes, is the most common inherited cardiac disease. Instead, RASopathies, a rare class of disorders characterized by neuro-cardio-facial-cutaneous abnormalities and sometimes presenting with LVH, are caused by mutations in the RAS-MAPK pathway. We report on a 62-years-old male who presented isolated severe obstructive LVH but did not carry the sarcomere mutation previously identified in his affected relatives. By exome sequencing, we detected a novel mutation in HRAS gene (NM-005343.2:p.Arg68Trp), present also in the proband's daughter, who showed mild LVH and severe intellectual disability. The cardiac phenotype was indistinguishable between family members carrying either mutation. In silico studies suggested that the mutated HRAS protein is constitutionally activated. Consistently, functional characterization in vitro confirmed elevated HRAS-GTP accumulation and downstream RAS-MAPK pathway activation that are known to drive cell proliferation in LVH. Our study emphasizes the role of RAS signaling in cardiac hypertrophy and highlights the complexity in differential diagnosis of RASopathies. In fact, the mild features of RASopathy and the recurrence of sarcomeric HCM in this family delayed the correct diagnosis until comprehensive genetic testing was performed.

UR - http://www.scopus.com/inward/record.url?scp=85007454209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007454209&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0168501

DO - 10.1371/journal.pone.0168501

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0168501

ER -